With recent debates on the cost of #HCV treatment, researchers may have found a way to reduce costs for direct acting antiviral medication by finding out when therapy can be safely discontinued.
Researchers have designed a model to use blood tests and therapy performance to determine a safe point for patients to safely stop treatments, reducing the costs and time of therapy.
